论文部分内容阅读
30余年来对多发性骨髓瘤(MM)患者的标准治疗是用梅尔法兰及强的松进行化疗,受治者预期寿命平均约为3年,用多疗法的初始治疗未能明显改善预后,因而对其它治疗方案进行了研究和检验,一个新的治疗方法是给患者加大细胞抑制剂用量并做或不做全身照射,这就需要给予造血干细胞以促进患者造血功能的恢复。但这种大多用HLA相符的兄弟姊妹所提供并保证无肿瘤的骨髓所进行的异体骨髓移植(KMT),与自体KMT相比,具移植物抗宿主反应,其发病率及致死率均较高。近10年
The standard treatment for patients with multiple myeloma (MM) for more than 30 years is chemotherapy with melphalan and prednisone. The average life expectancy of those treated is approximately 3 years. Initial treatment with multiple therapies failed to significantly improve the prognosis. Therefore, other treatment options have been studied and tested. A new treatment method is to increase the dosage of cytostatics and do or not to perform whole-body irradiation on the patients. This requires the administration of hematopoietic stem cells to promote recovery of hematopoietic function. However, this allogeneic bone marrow transplantation (KMT), which is provided by HLA-matched siblings and guarantees tumor-free bone marrow, has a graft-versus-host reaction compared to autologous KMT, and has a higher incidence and mortality. . Nearly 10 years